Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
Stilgenbauer, Stephan, Aurran Schleinitz, Thérèse, Eichhorst, Barbara, Lang, Fabian, Offner, Fritz, Rossi, Jean-François, Schroyens, Wilfried, Van Den Neste, Eric, Ysebaert, Loïc, von Wangenheim, Ute, Ursula Kress, Uta, Blum, Petra, Zenz, Thorsten
Published in Leukemia (01.10.2019)
Published in Leukemia (01.10.2019)
Get full text
Journal Article
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
Seibold, James R, Maher, Toby M, Highland, Kristin B, Assassi, Shervin, Azuma, Arata, Hummers, Laura Kathleen, Costabel, Ulrich, von Wangenheim, Ute, Kohlbrenner, Veronika, Gahlemann, Martina, Alves, Margarida, Distler, Oliver
Published in Annals of the rheumatic diseases (01.11.2020)
Published in Annals of the rheumatic diseases (01.11.2020)
Get full text
Journal Article
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
Westeel, Virginie, Schuette, Wolfgang, Urban, Thierry, Radonjic, Dejan, von Wangenheim, Ute, Lorence, Robert M, Reck, Martin
Published in PloS one (17.10.2023)
Published in PloS one (17.10.2023)
Get full text
Journal Article
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
Luedtke, Doreen, Marzin, Kristell, Jungnik, Arvid, von Wangenheim, Ute, Dallinger, Claudia
Published in European journal of drug metabolism and pharmacokinetics (01.10.2018)
Published in European journal of drug metabolism and pharmacokinetics (01.10.2018)
Get full text
Journal Article
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.10.2020)
Published in Investigational new drugs (01.10.2020)
Get full text
Journal Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.02.2021)
Published in Investigational new drugs (01.02.2021)
Get full text
Journal Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.02.2021)
Published in Investigational new drugs (01.02.2021)
Get full text
Journal Article
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Grosso, Federica, Steele, Nicola, Novello, Silvia, Nowak, Anna K, Popat, Sanjay, Greillier, Laurent, John, Thomas, Leighl, Natasha B, Reck, Martin, Taylor, Paul, Planchard, David, Sørensen, Jens Benn, Socinski, Mark A, von Wangenheim, Ute, Loembé, Arsène Bienvenu, Barrueco, José, Morsli, Nassim, Scagliotti, Giorgio
Published in Journal of clinical oncology (01.11.2017)
Published in Journal of clinical oncology (01.11.2017)
Get full text
Journal Article
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Scagliotti, Giorgio V, Gaafar, Rabab, Nowak, Anna K, Nakano, Takashi, van Meerbeeck, Jan, Popat, Sanjay, Vogelzang, Nicholas J, Grosso, Federica, Aboelhassan, Rasha, Jakopovic, Marko, Ceresoli, Giovanni L, Taylor, Paul, Orlandi, Francisco, Fennell, Dean A, Novello, Silvia, Scherpereel, Arnaud, Kuribayashi, Kozo, Cedres, Susana, Sørensen, Jens Benn, Pavlakis, Nick, Reck, Martin, Velema, Derek, von Wangenheim, Ute, Kim, Miyoung, Barrueco, José, Tsao, Anne S
Published in The lancet respiratory medicine (01.07.2019)
Published in The lancet respiratory medicine (01.07.2019)
Get more information
Journal Article
Single--crossover recombination and ancestral recombination trees
Get full text
Paper
Journal Article
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Forster, Martin, Hackshaw, Allan, De Pas, Tommaso, Cobo, Manuel, Garrido, Pilar, Summers, Yvonne, Dingemans, Anne-Marie C., Flynn, Michael, Schnell, David, von Wangenheim, Ute, Loembé, Arsene-Bienvenu, Kaiser, Rolf, Lee, Siow Ming
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2018)
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2018)
Get full text
Journal Article
Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial
Grosso, Federica, Steele, Nicola, Novello, Silvia, Nowak, Anna, Popat, Sanjay, Greillier, Laurent, von Wangenheim, Ute, Morsli, Nassim, Barrueco, Jose, Scagliotti, Giorgio
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma
Scagliotti, Giorgio V., Gaafar, Rabab, Nowak, Anna, Vogelzang, Nicholas J., Von Wangenheim, Ute, Morsli, Nassim, Velema, Derek, Popat, Sanjay
Published in Journal of thoracic oncology (01.10.2016)
Published in Journal of thoracic oncology (01.10.2016)
Get full text
Journal Article
Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM)
Scagliotti, Giorgio V., Gaafar, Rabab M., Nowak, Anna K., Van Meerbeeck, Jan P., Vogelzang, Nicholas J., von Wangenheim, Ute, Loembe, Arsene-Bienvenu, Morsli, Nassim, Velema, Derek, Popat, Sanjay
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)
Pavlakis, Nick, Grosso, Federica, Steele, Nicola L., Nowak, Anna K., Novello, Silvia, Popat, Sanjay, Greillier, Laurent, Reck, Martin, John, Tom, Taylor, Paul, Leighl, Natasha B., Ceresoli, Giovanni Luca, Sørensen, Jens Benn, Planchard, David, Hughes, Brett Gordon Maxwell, Mazieres, Julien, Socinski, Mark A., von Wangenheim, Ute, Barrueco, Jose, Scagliotti, Giorgio V.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Single-crossover recombination in discrete time
von Wangenheim, Ute, Baake, Ellen, Baake, Michael
Published in Journal of mathematical biology (01.05.2010)
Published in Journal of mathematical biology (01.05.2010)
Get full text
Journal Article
P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma
Scagliotti, Giorgio V., Gaafar, Rabab, Nowak, Anna, Vogelzang, Nicholas J., Von Wangenheim, Ute, Morsli, Nassim, Velema, Derek, Popat, Sanjay
Published in Journal of thoracic oncology (01.10.2016)
Published in Journal of thoracic oncology (01.10.2016)
Get full text
Journal Article
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients with Unresectable Malignant Pleural Mesothelioma
Scagliotti, Giorgio V, Gaafar, Rabab, Nowak, Anna K, Reck, Martin, Tsao, Anne S, van Meerbeeck, Jan, Vogelzang, Nicholas J, Nakano, Takashi, von Wangenheim, Ute, Velema, Derek, Morsli, Nassim, Popat, Sanjay
Published in Clinical lung cancer (01.09.2017)
Published in Clinical lung cancer (01.09.2017)
Get full text
Journal Article
Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
Nowak, Anna K., Grosso, Federica, Steele, Nicola, Novello, Silvia, Popat, Sanjay, Greillier, Laurent, John, Tom, Leighl, Natasha B., Reck, Martin, Pavlakis, Nick, Soerensen, Jens Benn, Planchard, David, Ceresoli, Giovanni Luca, Hughes, Brett Gordon Maxwell, Mazieres, Julien, Socinski, Mark A., Velema, Derek, von Wangenheim, Ute, Morsli, Nassim, Scagliotti, Giorgio V.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article